Cite
HARVARD Citation
Shum, E. et al. (n.d.). 407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A432. [Online].